The Effect of Granulocyte Colony Stimulating Factor (G-CSF) on Myocardial Function After Acute Anterior Myocardial Infarction, a Prospective Double Blind Randomized Placebo Controlled Study
NCT ID: NCT00756756
Last Updated: 2008-09-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
20 participants
INTERVENTIONAL
2007-06-30
2008-02-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Results: No severe side effects of G-CSF treatment were observed. Ejection fraction determined by cardiac scan increased in the treatment group from 0.428 to 0.462 and from 0.470 to 0.496 in the control group but there was no significant improvement of left ventricular ejection fraction when the G-CSF treated group was compared to the controls (p=0.821 for cardiac scan and p=0.705 for echocardiography). Changes in Tei index was not significant in the treatment group (p=0.815) however it reached significant level in the control group (p=0.005), respectively.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
post MI post PCI and G-CSF infusion
G-CSF
after 2 week post MI an d PCI G-CSF was infused for 5 days at dose of 10 microgram/Kg
2
post MI and post PCI only placebo infused
placebo infusion of normal saline
2 week post MI and PCI normal saline was infused
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
G-CSF
after 2 week post MI an d PCI G-CSF was infused for 5 days at dose of 10 microgram/Kg
placebo infusion of normal saline
2 week post MI and PCI normal saline was infused
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Low systolic ventricular function.
Exclusion Criteria
* Contraindication to G-CSF
* Cardiogenic shock
* Hemodynamic instability
* Hepatic or renal disease
* Multivessel disease
30 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shiraz University of Medical Sciences
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Shiraz University of medical sciences
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Shiraz University of Medical Sciences/Cardiology Ward/Namazi and Shahid Faghihi Hospital
Shiraz, Fars, Iran
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
86-3454
Identifier Type: -
Identifier Source: org_study_id